‘It’s made things worse for everyone’: Philadelphia grapples with rise of new street drug
Medetomidine has extreme and fast-acting withdrawal symptoms – and the detox centers that help patients are struggling with how best to cope
TL;DR
- Medetomidine, a veterinary sedative, is the latest dangerous drug to appear in Kensington, Philadelphia's notorious open drug scene.
- This drug, often mixed with fentanyl, causes extreme and fast-acting withdrawal symptoms, leading to organ damage and severe health issues.
- The prevalence of medetomidine is overwhelming local hospitals, with ICUs occupied by patients in withdrawal, and current treatment programs are inadequate.
- Medetomidine has replaced xylazine ('tranq') following a state ban, with drug cartels seeking to maximize profits by reducing drug duration and intensity.
- Activists and harm reduction advocates are calling for innovative solutions, including safe supply programs, as current approaches are insufficient to combat the crisis.